[{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Synthetic Tetrahydrocannabinol Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Kingswood Investments"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Cannabidiol","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Kingswood Investments"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"MZ Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Synthetic Tetrahydrocannabinol Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ MZ Group","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ MZ Group"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ MIRA Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ MIRA Pharmaceuticals"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Pharmaseed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ MIRA Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ MIRA Pharmaceuticals"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Frontage Laboratories, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Marijuana Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Mira Pharmaceuticals

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pp

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

02

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

03

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

04

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

05

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

06

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

07

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

08

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

09

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

10

Mira Pharmaceuticals

U.S.A

BIO CEO & Investor

Not Confirmed

1
2